BIOMARKER:

MET mutation

Entrez ID:

Related biomarkers:

‹

›

MET mutation MET mutation	Non Small Cell Lung Cancer NSCLC	MET mutation MET mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Resistant: C3 – Early Trials Thorac Cancer - 3 weeks (NewC3)	Immunotherapy Resistant: C3 – Early Trials Thorac Cancer - 3 weeks - (New C3)
MET mutation MET mutation	Renal Cell Carcinoma RCC	MET mutation MET mutation	Renal Cell Carcinoma RCC	savolitinib Sensitive: B - Late Trials	savolitinib Sensitive: B - Late Trials
MET mutation MET mutation	Gastric Cancer Gastric Cancer	MET mutation MET mutation	Gastric Cancer Gastric Cancer	TPX-0022 Sensitive: C2 – Inclusion Criteria	TPX-0022 Sensitive: C2 – Inclusion Criteria
MET mutation MET mutation	Non Small Cell Lung Cancer NSCLC	MET mutation MET mutation	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: C2 – Inclusion Criteria	crizotinib Sensitive: C2 – Inclusion Criteria
MET mutation MET mutation	Renal Cell Carcinoma RCC	MET mutation MET mutation	Renal Cell Carcinoma RCC	cabozantinib capsule Sensitive: C2 – Inclusion Criteria	cabozantinib capsule Sensitive: C2 – Inclusion Criteria
MET mutation MET mutation	Renal Cell Carcinoma RCC	MET mutation MET mutation	Renal Cell Carcinoma RCC	crizotinib Sensitive: C2 – Inclusion Criteria	crizotinib Sensitive: C2 – Inclusion Criteria
MET mutation MET mutation	Renal Cell Carcinoma RCC	MET mutation MET mutation	Renal Cell Carcinoma RCC	c-MET inhibitor Sensitive: C3 – Early Trials	c-MET inhibitor Sensitive: C3 – Early Trials
MET mutation MET mutation	Renal Cell Carcinoma RCC	MET mutation MET mutation	Renal Cell Carcinoma RCC	sunitinib Sensitive: C3 – Early Trials	sunitinib Sensitive: C3 – Early Trials
MET mutation MET mutation	Renal Cell Carcinoma RCC	MET mutation MET mutation	Renal Cell Carcinoma RCC	everolimus Sensitive: C3 – Early Trials	everolimus Sensitive: C3 – Early Trials
MET mutation MET mutation	Renal Cell Carcinoma RCC	MET mutation MET mutation	Renal Cell Carcinoma RCC	GSK1363089 Sensitive: C3 – Early Trials	GSK1363089 Sensitive: C3 – Early Trials
MET mutation MET mutation	Non Small Cell Lung Cancer NSCLC	MET mutation MET mutation	Non Small Cell Lung Cancer NSCLC	MTI-31 Sensitive: D – Preclinical	MTI-31 Sensitive: D – Preclinical